Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1.

Kimoto E, Vourvahis M, Scialis RJ, Eng H, Rodrigues AD, Varma MVS.

Drug Metab Dispos. 2019 May;47(5):493-503. doi: 10.1124/dmd.118.085241. Epub 2019 Mar 12.

PMID:
30862625
2.

No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV-1-Infected Subjects.

Vourvahis M, McFadyen L, Nepal S, Valluri SR, Fang A, Fate GD, Wood LS, Marshall JC, Chan PLS, Nedderman A, Haynes J, Savage ME, Clark A, Smith KY, Heera J.

J Clin Pharmacol. 2019 Jan;59(1):139-152. doi: 10.1002/jcph.1306. Epub 2018 Sep 7.

3.

Improving maraviroc oral bioavailability by formation of solid drug nanoparticles.

Savage AC, Tatham LM, Siccardi M, Scott T, Vourvahis M, Clark A, Rannard SP, Owen A.

Eur J Pharm Biopharm. 2019 May;138:30-36. doi: 10.1016/j.ejpb.2018.05.015. Epub 2018 May 17.

PMID:
29777772
4.

Towards a Maraviroc long-acting injectable nanoformulation.

Tatham LM, Savage AC, Dwyer A, Siccardi M, Scott T, Vourvahis M, Clark A, Rannard SP, Owen A.

Eur J Pharm Biopharm. 2019 May;138:92-98. doi: 10.1016/j.ejpb.2018.04.009. Epub 2018 Apr 21.

PMID:
29684534
5.

Pharmacokinetics, Safety and Efficacy of Maraviroc in Treatment-experienced Pediatric Patients Infected With CCR5-Tropic HIV-1.

Giaquinto C, Mawela MP, Chokephaibulkit K, Negra MD, Mitha IH, Fourie J, Fang A, van der Ryst E, Valluri SR, Vourvahis M, Zhang-Roper RY, Craig C, McFadyen L, Clark A, Heera J.

Pediatr Infect Dis J. 2018 May;37(5):459-465. doi: 10.1097/INF.0000000000001808.

6.

Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A.

Mao J, Martin I, McLeod J, Nolan G, van Horn R, Vourvahis M, Lin YS.

Drug Metab Rev. 2017 Feb;49(1):18-34. doi: 10.1080/03602532.2016.1239630. Epub 2016 Oct 20. Review.

PMID:
27718639
7.

Once-daily maraviroc versus tenofovir/emtricitabine each combined with darunavir/ritonavir for initial HIV-1 treatment.

Stellbrink HJ, Le Fevre E, Carr A, Saag MS, Mukwaya G, Nozza S, Valluri SR, Vourvahis M, Rinehart AR, McFadyen L, Fichtenbaum C, Clark A, Craig C, Fang AF, Heera J.

AIDS. 2016 May 15;30(8):1229-38. doi: 10.1097/QAD.0000000000001058.

8.

Clinical relevance of CYP3A5 genotype on maraviroc exposures.

Vourvahis M, McFadyen L, Heera J, Clark A.

Drug Metab Dispos. 2015 May;43(5):771-2. doi: 10.1124/dmd.115.063321. No abstract available.

9.

Single-dose pharmacokinetics, safety, and tolerability of modified-release formulations of lersivirine in healthy subjects.

Vourvahis M, Wang R, Mendes da Costa L, Wang C, Weatherley B, Mukwaya G, Tawadrous M, Heera J.

Clin Pharmacol Drug Dev. 2014 Nov;3(6):472-6. doi: 10.1002/cpdd.117. Epub 2014 May 26. No abstract available.

PMID:
27129121
10.

The effect of maraviroc on the pharmacokinetics of digoxin in healthy volunteers.

Vourvahis M, Fang J, Choo HW, Heera J.

Clin Pharmacol Drug Dev. 2014 May;3(3):202-6. doi: 10.1002/cpdd.91. Epub 2014 Feb 6. No abstract available.

PMID:
27128610
11.

The effects of boceprevir and telaprevir on the pharmacokinetics of maraviroc: an open-label, fixed-sequence study in healthy volunteers.

Vourvahis M, Plotka A, Kantaridis C, Fang A, Heera J.

J Acquir Immune Defic Syndr. 2014 Apr 15;65(5):564-70. doi: 10.1097/QAI.0000000000000090.

12.

Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjects.

Vourvahis M, Plotka A, Mendes da Costa L, Fang A, Heera J.

Antimicrob Agents Chemother. 2013 Dec;57(12):6158-64. doi: 10.1128/AAC.01098-13. Epub 2013 Sep 30.

13.

Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function.

Vourvahis M, Fang J, Checchio T, Milton A, Weatherley B, McFadyen L, Heera J.

HIV Clin Trials. 2013 May-Jun;14(3):99-109. doi: 10.1310/hct1403-99.

PMID:
23835512
14.

Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine.

Vourvahis M, Davis J, Langdon G, Layton G, Fang J, Choo HW, Hansson AG, Tawadrous M.

Antivir Ther. 2013;18(6):745-54. doi: 10.3851/IMP2566. Epub 2013 Apr 4.

PMID:
23558061
15.

Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study.

Mills A, Mildvan D, Podzamczer D, Fätkenheuer G, Leal M, Than S, Valluri SR, Craig C, McFadyen L, Vourvahis M, Heera J, Valdez H, Rinehart AR, Portsmouth S.

J Acquir Immune Defic Syndr. 2013 Feb 1;62(2):164-70. doi: 10.1097/QAI.0b013e31827b51b5.

PMID:
23187936
16.

Effect of lersivirine co-administration on pharmacokinetics of methadone in healthy volunteers.

Vourvahis M, Wang R, Gruener DM, Bruce RD, Haider S, Tawadrous M.

Drug Alcohol Depend. 2012 Nov 1;126(1-2):183-8. doi: 10.1016/j.drugalcdep.2012.05.009. Epub 2012 Jun 8.

PMID:
22682979
17.

Effect of rifampin and rifabutin on the pharmacokinetics of lersivirine and effect of lersivirine on the pharmacokinetics of rifabutin and 25-O-desacetyl-rifabutin in healthy subjects.

Vourvahis M, Davis J, Wang R, Layton G, Choo HW, Chong CL, Tawadrous M.

Antimicrob Agents Chemother. 2012 Aug;56(8):4303-9. doi: 10.1128/AAC.06282-11. Epub 2012 May 29.

18.

The effect of lersivirine, a next-generation NNRTI, on the pharmacokinetics of midazolam and oral contraceptives in healthy subjects.

Davis J, Langdon G, Layton G, Chong CL, Ndongo MN, Vourvahis M.

Eur J Clin Pharmacol. 2012 Nov;68(11):1567-72. doi: 10.1007/s00228-012-1287-5. Epub 2012 Apr 22.

PMID:
22527351
19.

The pharmacokinetics of lersivirine (UK-453,061) and HIV-1 protease inhibitor coadministration in healthy subjects.

Vourvahis M, Langdon G, Layton G, Labadie RR, Choo HW, Ndongo MN, Davis J.

J Acquir Immune Defic Syndr. 2012 May 1;60(1):24-32. doi: 10.1097/QAI.0b013e31824c4186.

PMID:
22517413
20.

No effect of a single supratherapeutic dose of lersivirine, a next-generation nonnucleoside reverse transcriptase inhibitor, on corrected QT interval in healthy subjects.

Vourvahis M, Wang R, Ndongo MN, O'Gorman M, Tawadrous M.

Antimicrob Agents Chemother. 2012 May;56(5):2408-13. doi: 10.1128/AAC.05194-11. Epub 2012 Feb 27.

21.

Pharmacokinetic effects of coadministration of lersivirine with raltegravir or maraviroc in healthy subjects.

Vourvahis M, Langdon G, Labadie RR, Layton G, Ndongo MN, Banerjee S, Davis J.

Antimicrob Agents Chemother. 2012 Feb;56(2):887-92. doi: 10.1128/AAC.00572-11. Epub 2011 Nov 28.

22.

Effects of ketoconazole and valproic acid on the pharmacokinetics of the next generation NNRTI, lersivirine (UK-453,061), in healthy adult subjects.

Langdon G, Davis J, Layton G, Chong CL, Weissgerber G, Vourvahis M.

Br J Clin Pharmacol. 2012 May;73(5):768-75. doi: 10.1111/j.1365-2125.2011.04136.x.

23.

Hemodynamic effects of single-dose vardenafil in subjects receiving maraviroc.

Vourvahis M, Fang J, Huyghe I, Heera J.

J Acquir Immune Defic Syndr. 2010 Jul;54(3):336-8. doi: 10.1097/QAI.0b013e3181d01c3c. No abstract available.

PMID:
20571416
24.

Lack of a clinically relevant effect of an antacid on the pharmacokinetics of lersivirine.

Vourvahis M, Banerjee S, LaBadie R, Gore D, Mayer H.

Antimicrob Agents Chemother. 2010 May;54(5):2209-11. doi: 10.1128/AAC.01110-09. Epub 2010 Feb 16.

25.

A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir.

Dumond JB, Vourvahis M, Rezk NL, Patterson KB, Tien HC, White N, Jennings SH, Choi SO, Li J, Wagner MJ, La-Beck NM, Drulak M, Sabo JP, Castles MA, Macgregor TR, Kashuba AD.

Clin Pharmacol Ther. 2010 Jun;87(6):735-42. doi: 10.1038/clpt.2009.253. Epub 2010 Feb 10.

26.

Excretion and metabolism of lersivirine (5-{[3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C]Lersivirine to healthy volunteers.

Vourvahis M, Gleave M, Nedderman AN, Hyland R, Gardner I, Howard M, Kempshall S, Collins C, LaBadie R.

Drug Metab Dispos. 2010 May;38(5):789-800. doi: 10.1124/dmd.109.031252. Epub 2010 Feb 2.

PMID:
20124396
27.

Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment.

Abel S, Davis JD, Ridgway CE, Hamlin JC, Vourvahis M.

Antivir Ther. 2009;14(6):831-7. doi: 10.3851/IMP1297.

PMID:
19812445
28.

Maraviroc: pharmacokinetics and drug interactions.

Abel S, Back DJ, Vourvahis M.

Antivir Ther. 2009;14(5):607-18. Review.

PMID:
19704163
29.

Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women.

Yeh RF, Rezk NL, Kashuba AD, Dumond JB, Tappouni HL, Tien HC, Chen YC, Vourvahis M, Horton AL, Fiscus SA, Patterson KB.

Antimicrob Agents Chemother. 2009 Jun;53(6):2367-74. doi: 10.1128/AAC.01523-08. Epub 2009 Mar 23.

30.

The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic Fatty liver disease and correlates with plasma caspase-3/7 activity.

Schrieber SJ, Wen Z, Vourvahis M, Smith PC, Fried MW, Kashuba AD, Hawke RL.

Drug Metab Dispos. 2008 Sep;36(9):1909-16. doi: 10.1124/dmd.107.019604. Epub 2008 Jun 19.

PMID:
18566043
31.

The pharmacokinetics and viral activity of tenofovir in the male genital tract.

Vourvahis M, Tappouni HL, Patterson KB, Chen YC, Rezk NL, Fiscus SA, Kearney BP, Rooney JF, Hui J, Cohen MS, Kashuba AD.

J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):329-33. doi: 10.1097/QAI.0b013e3181632cc3.

32.

Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir.

Vourvahis M, Kashuba AD.

Pharmacotherapy. 2007 Jun;27(6):888-909. Review.

PMID:
17542771

Supplemental Content

Loading ...
Support Center